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way to go,,  p
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aEl  cáncer  gástrico  en  México:  mejoría
Gastric  cancer  (GC)  is  the  second  cause  of  cancer-related
mortality  worldwide1 and  is  also  responsible  for  one  of  the
highest  cancer  burdens,  as  measured  by  disability-adjusted
life  years  lost.2 Approximately  65%  of  GC  patients  present
with  locally  advanced  or  metastatic  disease,  and  the  major-
ity  will  have  systemic  disease  at  some  time  during  the  course
of  their  illness.3
In  this  issue  of  the  Revista  Mexicana  de  Gastroen-
terología,  Sánchez-Barriga4 reported  that  between  2002-
2012,  69,107  patients  in  Mexico  died  from  GC.  In  the  year
2000,  there  were  5,003  deaths  from  GC  and  in  2012,  5,459
individuals  died  from  this  malignancy.  The  mortality  rate
adjusted  for  age  for  GC  was  5.6  per  100,000  inhabitants  in
2012,  and  this  study  showed  that  the  mortality  rate  from
GC  in  Mexico  decreased  from  7.5  per  100,000  inhabitants  in
2000.4 Some  notes  of  caution  are  in  order.  Mortality  rates
may  be  modiﬁed  over  time,  due  to  improved  diagnosis,  bet-
ter  medical  care,  increase  in  identiﬁcation  of  cases,  and
better  records,  as  well  as  changes  in  the  prevalence  of  risk
factors.  The  study  by  Sánchez-Barriga  emphasizes  the  asso-
ciation  between  poverty  and  GC.  The  state  of  Chiapas  had
the  highest  poverty  rate  in  Mexico  in  2012,5 with  74.7%  of
the  population  living  in  extreme  poverty.4 This  state  also
had  the  highest  death  rate  from  GC  in  2000  (9.2;  95%  CI:
8.2-10.3)  and  in  2012  (8.2;  95%  CI:  7.3-9).  Furthermore,  Chi-
apas  had  the  highest  rate  of  years  of  potential  life  lost  rate
during  the  study  period  (97.4  in  2000  and  79.6  in  2012).
This  association  could  be  explained  by  the  higher  preva-
lence  of  H.  pylori  infection  in  rural  areas,  where  potable
water  is  limited  and  poor  sanitary  conditions  are  frequent.
H.  pylori  infection  is  estimated  to  account  for  more  than
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0%  of  GC,6 and  more  than  5%  of  all  cancer  worldwide.7
oreover,  treatments  to  eradicate  H.  pylori  infection  in
symptomatic  subjects  have  been  shown  to  decrease  the
requency  of  both  precancerous  gastric  lesions  and  GC  in
sian  countries.8
This  study  also  highlights  the  fact  that  GC  is  an  aggressive
isease  with  a  high  mortality  rate,  and  that  the  majority  of
C  patients  in  clinical  practice  have  advanced  disease  at
iagnosis.  Despite  the  progress  made  in  diagnosis,  surgical
echniques,  chemotherapy,  and  radiotherapy,  prognosis  for
C  remains  poor.
Currently,  in  rural  areas  in  North  America  with  an
ncreased  incidence  of  H.  pylori  infection  and  GC,9 there  are
orking  groups  whose  goal  is  to  identify  effective  treatment
trategies  and  develop  recommendations  for  health  policy
imed  at  management  of  H.  pylori  infection  and  reduction
f  GC.  In  addition,  screening  for  GC  could  be  useful  in  detec-
ing  asymptomatic  patients  with  early  GC  in  high-prevalence
reas,10 which,  in  turn,  would  increase  the  number  of  treat-
ble  cancers  and  improve  overall  survival.  Therefore,  the
doption  of  such  strategies  should  be  considered  for  areas
n  Mexico  with  a  high  prevalence  of  GC.
In  conclusion,  despite  the  reduction  in  the  incidence
f  GC  in  Mexico  comparable  to  the  decrease  in  incidence
orldwide,7 this  disease  continues  to  be  a  major  health
roblem  in  Mexico,  with  a  signiﬁcantly  negative  social
mpact  from  the  premature  deaths  caused  by  GC.  Three
ajor  potential  areas  for  development  should  be  recog-
ized:  1)  Improved  sanitation  and  access  to  potable  water
ould  result  in  a  further  reduction  of  prevalence  of  H.  pylori
nfection  and  GC;  2)  GC  screening  for  early  recognition
f  high-risk  patients  for  GC,11 such  as  those  with  atrophic
astritis,  intestinal  metaplasia,  gastric  ulcer,  or  dyspla-
ia,  especially  in  areas  with  the  least  favorable  education,
ccupation,  health,  housing,  and  employment  conditions;
nd  3)  Improvements  in  GC  therapy,  which  are  expected
s  our  understanding  of  GC  biology  and  signaling  path-
ays  improves.  The  integration  of  targeted  therapies  is
lready  possible  and  early  results  are  promising.  Better
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herapy  selection  for  individual  patients  may  also  signiﬁ-
antly  improve  treatment  and  patient  survival.
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